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The spike (S) protein of SARS coronavirus (SARS-CoV) is responsible for viral binding with ACE2 molecules. Its receptor-binding motif (S-
RBM) is located between residues 424 and 494, which folds into 2 anti-parallel β-sheets, β5 and β6. We have previously demonstrated that
fragment 450–650 of the S protein (S450–650) is predominantly recognized by convalescent sera of SARS patients. The N-terminal 60 residues
(450–510) of the S450–650 fragment covers the entire β6 strand of S-RBM. In the present study, we demonstrate that patient sera predominantly
recognized 2 linear epitopes outside the β6 fragment, while the mouse antisera, induced by immunization of BALB/c mice with recombinant
S450–650, mainly recognized the β6 strand-containing region. Unlike patient sera, however, the mouse antisera were unable to inhibit the
infectivity of S protein-expressing (SARS-CoV-S) pseudovirus. Fusion protein between green fluorescence protein (GFP) and S450–650 (S450–
650-GFP) was able to stain Vero E6 cells and deletion of the β6 fragment rendered the fusion product (S511–650-GFP) unable to do so. Similarly,
recombinant S450–650, but not S511–650, was able to block the infection of Vero E6 cells by the SARS-CoV-S pseudovirus. Co-precipitation
experiments confirmed that S450–650 was able to specifically bind with ACE2 molecules in lysate of Vero E6 cells. However, the ability of
S450–510, either alone or in fusion with GFP, to bind with ACE2 was significantly poorer compared with S450–650. Our data suggest a
possibility that, although the β6 strand alone is able to bind with ACE2 with relatively high affinity, residues outside the S-RBM could also assist
the receptor binding of SARS-CoV-S protein.
© 2006 Elsevier Inc. All rights reserved.Keywords: SARS-CoV; S protein; Receptor-binding motif; B cell epitopeIntroduction
SARS-associated coronavirus (SARS-CoV) is a positive-
stranded RNA virus of the Coronaviridae family. It is the
causative agent of severe acute respiratory syndrome (SARS)
and infected over 8000 people around the world in 2002–2003
(Peiris et al., 2003; Rota et al., 2003). The genome of SARS-
CoV encodes several structural proteins including the spike (S)
glycoprotein, nucleocapsid protein, membrane protein and
envelope protein (Marra et al., 2003). The S protein of SARS-
CoV is consisted of 1255 amino acid residues with approxi-⁎ Corresponding author. Fax: +86 10 82801156.
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doi:10.1016/j.virol.2006.09.022mately 25% homology to that of the other human CoVs (Ho et
al., 2004; Spiga et al., 2003). It mediates viral binding to
angiotensin-converting enzyme-2 (ACE2), a cell surface zinc
peptidase (Li et al., 2003). The S protein receptor-binding
domain (S-RBD) was mapped to a fragment between residues
318 to 510 (Wong et al., 2004). Li et al. (2005) have recently
solved the crystal structure of S-RBD complexed with ACE2 at
2.9 Å resolution. Their results demonstrate that S-RBD contains
2 subdomains: a core (residues 318 to 423) and an extended
loop (residues 424 to 494). The latter, referred as the S protein
receptor binding motif (S-RBM), is formed by 2 anti-parallel β-
sheets (β5 and β6) folding into a gently concave surface, which
makes all contacts with the ACE2 molecule (Li et al., 2005).
Interestingly, 9 out of the 14 amino acid residues of S-RBM in
direct contact with ACE2 are in the β6 strand (residues 450 to
363J. Zhao et al. / Virology 359 (2007) 362–370494), suggesting a possibility that the β6 fragment alone might
be able to bind with ACE2 with considerable affinity.
As the receptor binding site of SARS-CoV, S-RBD is the
most likely target for neutralizing Abs against the virus. Several
groups have mapped a number of B cell epitopes in, or around,
the S-RBD region (Hu et al., 2005; Hua et al., 2004, 2005; Lu
et al., 2005; Wang et al., 2003), although the exact location and
conformational structure of such epitopes remain to be clarified.
Our previous results demonstrated that SARS patients mounted
early and strong humoral responses against fragment 450–650
of the S protein (S450–650) (Zhao et al., 2005a, 2005b), which
contains the β6, but not β5, strand of the S-RBM. We herein
analyze the receptor binding ability of S450–650 and also its
antigenicity in terms of recognition by Abs.
Results
Expression and purification of recombinant truncated
polypeptides of S450–650 and their fusion products with GFP
Preparation of recombinant S450–650 was as previously
described (Zhao et al., 2005a, 2005b). DNA encoding truncated
fragments covering the sequence of S450–650, namely S-I
(450–510), S-II (511–560), S-III (546–595), S-IV (581–630)
and S-V (601–650), were amplified by PCR using vector
pET28a-S450–650 (encoding for S450–650 of SARS-CoV) as
template. The resultant products were inserted into prokaryotic
expression vector pET28a. DNA encoding GFP was inserted
downstream the S protein genes for preparation of GFP fusion
proteins S450–650-GFP, S450–510-GFP and S511–650-GFP
(Fig. 1A). Glycine- and serine-rich linkers of various length
have been widely used in protein engineering since these linkers
may offer little structure hindrance to folding proteins in their
own constructs (Liu et al., 2005; Nardella et al., 2004). A linker
sequence (GSGGSGS) was therefore introduced between S
fragment and GFP. The recombinant products, expressed in E.
coli, were purified to more than 90% homogeneity using Ni
columns and examined by SDS-PAGE electrophoresis (Figs. 1B
and 2).
Possible B cell epitopes in S450–650
Previous studies have demonstrated the presence of B cell
epitopes in S-RBD by screening synthetic or recombinant
polypeptides covering its sequence in ELISA or WB assays
(Chen et al., 2004; Zhang et al., 2004). To further map the B cell
epitopes in the S450–650 region, a set of convalescent patient sera
(PT31, PT41, PT42, PT53, and PT58), all tested positive in SARS-
CoV-based ELISA as previously described (Zhao et al., 2005a),
were screened in WB experiments against recombinant S-I, S-II,
S-III, S-IVand S-V. As illustrated in Fig. 2, S-II (511–560) and S-
IV (581–630) were strongly recognized by all 5 patient sera, while
none of the other overlapping constructs produced detectable
signals. These results imply that fragments between residues 511–
545 and 596–600 represent either linear B cell epitopes or parts of
conformational B cell epitopes predominantly recognized by
human Abs produced following an infection of SARS-CoV.BALB/c mice were s.c. immunized with recombinant S450–
650 emulsified in CFA and subsequently tested for serum Abs
against the immunizing Ag and also its truncated polypeptides
in WB assays. In contrary to that obtained with patient sera, the
mouse anti-serum strongly recognized S-I, weakly recognized
S-III and S-IV but did not recognize S-V (Fig. 2).
Comparison of the neutralization ability of patient sera and
mouse antiserum
By co-transfecting 293T cells with a SARS-CoV-S-protein-
expressing vector and a defective HIV-1-genome-expressing
luciferase, we prepared S-protein expressing pseudovirus. The
pseudovirus thus obtained was able to infect ACE2-positive Vero
E6 cells in vitro, evidenced by the approximately 100,000 folds
increase of luciferase activity in the infected cells (Fig. 3A). The
system was employed to compare the neutralization ability of
patient sera and mouse antiserum. As shown in Fig. 3B,
convalescent patient sera (PT31 and PT53), but not mouse anti-
S450–650 antiserum, were able to specifically neutralize S-
protein-expressing pseudovirus infection of Vero E6 cells,
implying that Ab specificity for linear epitopes in the β6 strand
is not necessarily associated with neutralization ability. Both
human and mouse sera tested herein were unable to neutralize the
infectivity of VSV-G pseudovirus (Fig. 3C), confirming the
specificity of the system.
Staining of Vero E6 cells using S450–650 or its GFP fusion
proteins
To assess the receptor binding ability of the S450–650
fragment, Vero E6 cells were treated with recombinant S450–
650 followed by either convalescent patient serum (PT31), or
control serum sample (HDS), or mouse anti-S450–650
antiserum (MAS), or normal mouse serum (NMS). S-RBD-
Fc is a fusion protein between the S-RBD domain (residues
318–510) and Fc fragment of human IgG1. It has been shown
to be able to bind with ACE2 receptor with high affinity
(Kuba et al., 2005). As controls, S-RBD-Fc and human IgG-
Fc were used to treat Vero E6 and also ACE2-negative 293T
cells. After washes, the cells were subsequently treated with
FITC-conjugated secondary Abs for FACS analysis. As
illustrated in Figs. 4A and B, S450–650-treated Vero E6
cells were specifically recognized by patient serum PT31 or
mouse anti-S450–650 antiserum, indicating specific binding
of the recombinant S450–650 to the cell surface. To further
locate the site for receptor binding within the 450–650
construct, we next employed fusion proteins S450–510-GFP,
S511–650-GFP and S450–650-GFP for direct staining of
Vero E6 and 293T cells. As expected, S450–650-GFP was
able to label Vero E6, but not 293T cells and deletion of the
450–510 sequence completely abolished its ability of doing
so (Figs. 4D and E). It is noteworthy that the intensity of
Vero E6 cell staining by S450–650 (Fig. 4B) and S450–650-
GFP (Fig. 4D) was approximately 50% of that by S-RBD-Fc
(Fig. 4C), while the fluorescence intensity of the S450–510-
GFP-stained cells was only 1/20 of that stained by S-RBD.
Fig. 1. Relative locations of the S-RBD, S-RBM and recombinant polypeptides prepared in this study. (A) Recombinant S450–650 and truncated polypeptides
covering its sequence, including S-I (450–510), S-II (511–560), S-III (546–595), S-IV (581–630), S-V (601–650) and S511–650 were expressed in E. coli.
Recombinant GFP and its fusion proteins with S protein fragments were also prepared. (B) The purifications product of GFP (lane 1) and its fusion proteins with S-I
(S450–510-GFP, lane 2), S511–650 (S511–650-GFP, lane 3) or S450–650 (S450–650-GFP, lane 4) were analyzed by SDS-PAGE electrophoresis and visualized by
Commassie blue staining. Molecular weight markers were loaded in the left-hand-side lane.
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infection of Vero E6 cells
Fig. 5A illustrates that the S-RBD-Fc fusion protein was able
to block the pseudovirus infection of Vero E6 cells with an IC50
of 0.4 μM. If the recombinant S450–650 polypeptide can
specifically bind with cellular receptors for S protein, it should
also be able to block the infection of host cells by SARS-CoVorSARS-CoV-S pseudovirus. As shown in Fig. 5B, S450–650
inhibited the infection of Vero E6 cells by SARS-CoV-S
pseudovirus with an IC50 of 0.8 μM, while the S511–650
polypeptide did not show any significant inhibitory effect.
Coinciding with the direct staining results illustrated in Fig. 4,
the S-I fragment (residues 450 to 510) was much less efficient in
blocking the SARS-S pseudovirus infection of Vero E6 cells
(Fig. 5B).
Fig. 2. Possible B cell epitopes in S450–650. Recombinant constructs S-I (450–
510), S-II (511–560), S-III (546–595), S-IV (581–630) and S-V (601–650)
were run on SDS-PAGE 12% gels (0.5 μg in each lane) and visualized by
Commassie blue staining (top row). The protein bands were transferred onto
nitrocellulose membranes for WB with convalescent patient sera (PT31, PT41,
PT42, PT53, PT58) or mouse anti-S450–650 antiserum (MAS) as first Abs.
HRP-conjugated goat anti-human, or goat-anti-mouse, IgG Abs were employed,
respectively, as detection Abs.
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In the experiment shown in Fig. 6, Vero E6 cells were treated
with recombinant S450–650, washed and then lysed using lysis
buffer. The lysate was treated sequentially with PT31 serum and
protein A/G-agarose for precipitation of the S450–650/ACE2
complexes. The resultant precipitates were run on SDS-PAGE
gels and assayed by WB with anti-ACE2 Abs as first Abs. Fig
6B illustrates that the PT31-precipitated materials contained
ACE2 molecules (120 kDa band specifically recognized by goat
anti-human ACE2 Abs). In parallel experiments, the S450–650-
treated cell lysate was precipitated using goat anti-human ACE2
polyclonal Abs and then the precipitates analyzed by WB using
PT31 serum as the first Abs. A 31 kDa protein band,
corresponding to the size of the S450–650 polypeptide, was
clearly visualized (Fig. 6C).Fig. 3. Comparison for neutralization ability of patient sera and mouse antiserum. (
pseudovirus, or VSV-G pseudovirus, or mock transfection supernatant (Control) were
(8×103 cells/well) and incubated at 37 °C for 1 h. The incubation continued for 48
activity in the lysate determined. The results are expressed as luciferase activity (log10
patients (PT31 and PT53), or healthy blood donors (HDS), or S450–650-immunized
SARS-CoV-S, or VSV-G, pseudovirus, and incubated for 30 min at 37 °C. The m
monolayer of Vero E6 cells. Luciferase activity in the infected cells was determined 4
group (Vero E6 cells only treated with pseudovirus preparations).Discussion
Identification of neutralizing epitopes in the S protein is of
great interest for vaccine design and also our understanding of
anti-SARS-CoV humoral immunity in patients. It has been
demonstrated that the S-RBD (residues 318–510) contains
immunodominant B cell epitopes and some of which are
recognized by neutralizing Abs (He et al., 2005; He et al., 2004;
Sui et al., 2004). Presumably, the neutralizing epitopes are
located within the S-RBM region (residues 424–494) which
forms direct contacts with ACE2 (Li et al., 2005). However, this
has so far not been confirmed by experimental data. In our WB
assays, the β6 strand (i.e. SI or S450–510) was not recognized
by convalescent patient sera (Fig. 2). Although the β6 strand
was predominantly recognized by antisera from mice after
immunization with the S450–650 construct (Fig. 2), such Abs
did not show neutralization ability against SARS-CoV-S
pseudovirus infection (Fig. 3). By immunizing mice with the
S-RBD-Fc, which adopts a natural fold of the S-RBD (Kuba et
al., 2005), He et al. (2005) generated a panel of mAbs, two of
which were specific for linear epitopes between residues 450
and 510, neither of these mAbs was able to neutralize viral
infection. This is in agreement with our data, shown in Fig. 3,
and indicates that the lack of neutralization ability of the mouse
Abs specific for linear sequences in the β6 strand is likely a
genuine phenomenon rather than the result of improper
presentation in the context of the peptides.
It should also be emphasized, however, that the above results
do not exclude the possibility that the β6 strand, or the whole S-
RBM fold formed by β5 and β6 strands together, contains
conformation- dependent B cell epitopes predominantly
recognized by neutralizing Abs. In WB assays, the reducing
and denaturing nature of SDS-PAGE would only allow protein
Ags to be recognized in linear form.
Our WB results also show that 2 fragments near the S-RBM
(residues 511 to 545 and 596 to 600) were specifically recognized
by all 5 patient sera tested (Fig. 2). Whether binding of human
Abs to these epitopes contributes to neutralization is still unclear,A) Infectivity of the SARS-CoV-S pseudovirus. Preparations of SARS-CoV-S
added to triplicate wells on 96-well plates containing monolayer of Vero E6 cells
h after fresh medium replacement and the cells were then lysed and luciferase
). (B and C) Neutralization assay. Serial diluted serum samples from convalescent
mice (MAS), or naïve BALB/c mice (NMS) were mixed with medium containing
ixtures were then distributed into triplicate wells in 96-well plates containing
8 h later and the results expressed as percent infection compared with the control
Fig. 4. Staining of Vero E6 cells with S450–650 or its GFP fusion proteins. For indirect staining (A, B), Vero E6 cells were treated with S450–650 (0.5 μM) in PBS at
4 °C for 1 h, followed by convalescent patient serum (PT31), or mouse anti-S450–650 antiserum (MAS), or serum sample from healthy blood donors (HDS), or normal
mouse serum (NMS). FITC-conjugated goat anti-human, or goat-anti-mouse, IgG Abs were employed as secondary Abs. As controls, Vero E6 cells and 293T cells
were treated with S-RBD-Fc, or human IgG (0.5 μM), at 4 °C for 1 h and followed by FITC-conjugated goat anti-human IgG (C, F). For direct staining, Vero E6 (D), or
293T (E), cells were treated with GFP, S450–510-GFP, S510–650-GFP or S450–650-GFP (0.5 μM) at 4 °C for 30 min. After washes, the cells were subjected to flow
cytometric analysis.
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targeted at the 511–545 and 596–600 epitopes) and neutralization
ability of convalescent sera provide circumstantial evidence for
this notion (JC Zhao, unpublished observation). Furthermore,
data reported by Li et al. (2005) and He et al. (2005) suggest that
Ab binding to regions near the S-RBM fold may cause
conformational change of the receptor binding sites, resulting in
inhibition of the RBD binding to ACE2.
Although the S450–650 construct contains only half of the
S-RBM fold (β6 but not the β5 strand), it is nonetheless able to
bind to ACE2 with relatively high affinity, as determined in
cellular staining, pseudovirus inhibition assays and co-pre-
cipitation experiments (Figs. 4, 5 and 6). This is also supportedFig. 5. Pseudovirus infection blocking assay. SARS-CoV-S pseudovirus preparation
incubated together for 30 min at 37 °C. The mixtures were then distributed into tripl
previously. Luciferase activity in the infected cells was determined 48 h later (A). In
with, or without (reference group), recombinant GFP, S450–650, S450–510-GFP or
are expressed as percent infection (luciferase activity of experimental group comparby Hu et al. who documented that recombinant S471–503
blocked the binding between S-RBD and ACE2 (Hu et al.,
2005). Additionally, our computer modeling results show that
the β6 strand contributes significantly more than β5 in terms of
contact area (238 vs. 17 Å2) as well as binding energy (139 vs.
30.6 kJ/mol) when interacting with ACE2 (Fig. 7).
An unexpected finding of this study is that construct S450–
510, either alone or in fusion with GFP, was relatively poor in
binding to ACE2 compared with S450–650, as determined in
both Vero E6 cell staining (Fig. 4D) and SARS-CoV-S
pseudovirus inhibition (Fig. 5B) experiments. There are several
possible explanations for this phenomenon. In the case where
GFP-fusion proteins were employed, it is possible that thes were mixed with, or without (reference group), RBD-Fc or human IgG and
icate wells containing monolayer of Vero E6 cells seeded on 96-well plates 18 h
a parallel experiment (B), SARS-CoV-S pseudovirus preparations were mixed
S510–650 at 37 °C for 30 min and then used to infect Vero E6 cells. The results
ed with that of the reference group).
Fig. 6. Co-precipitation of recombinant S450–650 with ACE2 in the lysate of Vero E6 cells. Vero E6 cells (1×106) were sequentially treated with goat anti-human
ACE2 Abs, or goat IgG (2 μg), and FITC-conjugated rabbit anti-goat IgG. The stained cells were subjected to flow cytometric analysis for determination of ACE2
expression on the cell surface (A). For the co-precipitation experiment (B), Vero E6 cells (2.5×107) were treated with, or without, recombinant S450–650 (15 μg/ml) at
4 °C for 1 h. After washes, the cells were lysed using lysis buffer and the lysate treated with PT31 serum followed by protein-A/G-agarose precipitation. The
precipitated materials were run on SDS-PAGE 12% gels and the protein bands transferred to nitrocellulose membranes for WB assays using goat anti-human ACE2
Abs as the first Abs, the detection Abs were HRP-labeled rabbit anti-goat IgG. In a parallel experiment (C), lysate of the S450–650-treated, or untreated, Vero E6 cells
were precipitated using goat anti-human ACE2 Abs and protein-A/G-agarose. The precipitates were assayed byWB using PT31 serum (first Ab) and HRP-labeled goat
anti-human IgG (detection Ab).
367J. Zhao et al. / Virology 359 (2007) 362–370ACE2-binding site on a ∼5.5 kDa peptide could be physically
blocked by the >20 kDa GFP. This blocking effect is
significantly lessened in S450–650-GFP construct that binds
ACE2 efficiently, perhaps because of a buffering effect of
residues 511–650 between β6 (i.e. 450–510) and GFP. In
addition, by starting the molecule from the middle of the S-
RBM fold, the S450–650 might be prone-to-misfold. Thirdly,
sequences adjacent to S-RBM may also assist the receptor
binding of S-RBM in a yet unknown mechanism. By virtue of
the formation of inter or intra-molecular disulfide bonds, the
binding of S450–650 polypeptide for ACE2 could be
stabilized and enhanced as well. Xiao et al. (2004) foundFig. 7. ACE2 interaction with the β5 and β6 strands of S-RBM. (A) Crystal structu
workers (Li et al., 2005). Details of the binding interface between S-RBM and the A
shown in panels B and C, respectively. The S protein-binding areas of the ACE2 mole
energy here is the energy required to disassemble the RBD-ACE2 complex into sep
energy calculated by SPDBV. PDB file accession number is 2AJF.that a dimeric state of S1 portion of the S protein could
contribute to an increased overall affinity that may enhance
fusion efficiency. This hypothesis may help explaining the fact
that Abs against regions adjacent to the S-RBM exhibit
neutralizing potential.
Materials and methods
Molecular biology reagents and cell culture
High fidelity Taq DNA polymerase was purchased from
TaKaRa Biotech Co. Ltd. (Shiga, Japan). Restriction enzymesre of the RBD in complex of human receptor ACE2 as reported by Li and co-
CE2 molecule and calculation results of the contact area and binding energy are
cule (purple) are colored in green and the β5 and β6 strands in gold. The binding
arate parts. The figure is prepared using PYMOL and contact area and binding
368 J. Zhao et al. / Virology 359 (2007) 362–370and T4 ligase were from Invitrogen (California, USA). A kit
for DNA extraction and purification was from Qiagen (Hilden,
Germany). E. coli strain of BL21 (DE3) was from Stratagene
(La Jolla, California, USA). The Ni-nitrilotriacetic acid (Ni-
NTA) resin was from Novagen (Darmstadt, Germany). Protein
A/G-agarose for immunoprecipitation was supplied by Santa
Cruz Biotechnology, Inc. (California, USA). The cell transfec-
tion reagent was from Vigorous Biotech Co. (Beijing, China).
Luciferase assay reagent was supplied by Promega (Madison,
USA). Goat anti-human ACE2 ectodomain polyclonal Abs
was purchased from R&D systems (Minneapolis, MN, USA).
FITC-conjugated rabbit anti-goat, goat anti-human, goat anti-
mouse IgG, horseradish peroxidase (HRP)-labeled goat anti-
human and goat anti-mouse IgG were obtained from
Zhongshan Biotech Co. (Beijing, China). Vero E6 cells and
293T cells were obtained from ATCC and propagated in
DMEM supplemented with 10% fetal bovine serum (Hyclone,
Utah, USA).
Subjects and blood samples
Serum samples used in this study were from convalescent
SARS patients, collected between July and August 2003 by the
Beijing Red Cross Center. The blood samples were processed
within 18 h of collection. In addition, a control serum sample
(HDS) was prepared by mixing sera from 10 randomly selected
healthy blood donors.
Expression and purification of recombinant proteins
Expression vector containing the gene for S450–650
(pET28a-S450–650) was as previously described (Zhao et al.,
2005a, 2005b). DNA encoding truncated fragments of S450–
650 was PCR amplified using pET28a-S450–650 as template.
A vector containing the gene for green fluorescence protein
(GFP) was a gift from Dr. L. Barber, Imperial College School of
Science, Technology and Medicine, London. For preparation of
GFP fusion proteins, a linker sequence (–Gly–Ser–Gly–Gly–
Ser–Gly–Ser–) was added between the S protein fragment and
GFP using sequence overlapping extension PCR method. The
DNA sequences encoding for S protein fragments or their
GFP fusion proteins were inserted into pET28a expression
vector. Recombinant products were expressed in E. coli and
purified using Ni-NTA resin following the manufacturer's
instructions. The preparation of S-RBD-Fc, a recombinant
fusion protein between S-RBD (residues 318–510) and the Fc
portion of human IgG1, was expressed in CHO cells and
purified by chromatography as described elsewhere (Kuba
et al., 2005).
Animal immunization and serum collection
Female BALB/c mice of 6–8 weeks of age, obtained from
the Institute of Genetics and Developmental Biology, Chinese
Academy of Sciences, Beijing, China, were immunized s.c.
with recombinant S450–650 (50 μg/mouse/100 μl), or PBS,
emulsified in complete Freund's adjuvant (CFA, Sigma, USA)at the base of the tail. Booster immunizations were given on
days 15 and 29 with S450–650 emulsified in incomplete
Freund's adjuvant (IFA). The mice were bled for sera a week
after the third immunization and the serum samples were kept at
−80 °C until use.
Immunoprecipitation (IP) and Western blot
The procedure for IP-Western blot assay was according to
that by Li et al. (2003). Briefly, Vero E6 cells (2.5×107) were
treated with, or without, recombinant S450–650 (15 μg) at
4 °C for 1 h. The cells were washed 3 times and then lysed in
lysis buffer containing 0.5% NP-40 and protease inhibitors
(pepstinin, leupeptin and aproptinin, all from Sigma). After
removal of cell debris by centrifugation, the lysate was allowed
to mix with either PT31 serum (1:200 diluted) or goat-anti-
human ACE2 Abs (2 μg/ml final concentration) at 4 °C
overnight. Sera from healthy subjects (HDS) and goat IgG were
also included as controls. Protein A/G-agarose was then added
and incubated at 4 °C for 1 h, followed by 3 washes. Bound
proteins were eluted in Laemmli sample buffer, at 90–100 °C
for 10 min, and separated on SDS-PAGE 12% gels. The protein
bands were transferred onto nitrocellulose membranes for WB
assays using goat anti-human ACE2 Abs or PT31 serum as the
first Abs.
The nitrocellulose membrane, on which the recombinant
proteins were transferred from SDS-PAGE gels, were blocked at
room temperature for 2 h with blocking solution (5% non-fat
dry milk) and then incubated for 2 h at room temperature with
convalescent sera of SARS patients (1:200 diluted) or antisera
from mice after S450–650 immunization (1:1000 diluted).
After washes in Tris-buffered saline (TBS, pH7.5) containing
0.05% Tween 20 (TBS-T), the membranes were incubated with
HRP-labeled goat anti-human or anti-mouse IgG. 3,3′-diami-
nobenzidine tetrahydrochloride (DAB, Sigma) was used to
visualize the reaction.
Indirect and direct staining of Vero E6 cells
For indirect staining experiments, Vero E6 cells (1×106)
were treated with recombinant S450–650 (0.5 μM) at 4 °C for
1 h. After 3 washes, the cells were incubated at 4 °C for 30 min
in the presence of patient sera (1:100 diluted) or mouse anti-
S450–650 antiserum (1/200 diluted). Serum samples from
healthy blood donors or naive BALB/c mice were included as
controls. Recombinant S-RBD-Fc and human IgG-Fc were also
employed to treat Vero E6 cells (0.5 μM, 4 °C for 1 h) as
controls. After washes, the cells were incubated with FITC-
conjugated goat anti-human or goat-anti-mouse IgG at 4 °C for
30 min and analyzed with FACScan (BD).
For direct staining experiments, Vero E6 cells (1×106) were
treated with GFP or GFP fusion proteins (0.5 μM) at 4 °C for
30 min, followed by flow cytometric analysis using a FACScan
machine. GFP has a single excitation peak at 490 nm and
emission peak at 509 nm, which adapts to common fluorescein
isothiocyanate (FITC) bandpass of FACS (Gerdes and Kaether,
1996).
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Preparation of SARS-CoV-S-protein- expressing pseudo-
virus was according to the method of Nie et al. (2004). Briefly,
293T cells (5×106), seeded in 10 cm diameter tissue culture
dishes one day earlier, were co-transfected with defective HIV-1
genome pNL4.3-Luc-R−E− (20 μg) and plasmid pVSV-G
(10 μg), encoding for vesicular stomatitis virus (VSV) G
protein, or plasmid pCMV-S, encoding for the S protein of
SARS-CoV, using the Vigorous transfection reagent (Vigorous
Biotech Co., Beijing, China). The defective HIV-genome
contains the gene for luciferase which can be used as a reporter
of successful infection by the pseudovirus. The culture medium
was replaced with fresh medium 24 h post-transfection and the
cells cultured for additional 24 h. The culture supernatant,
containing VSV-G-pseudovirus or SARS-S-pseudovirus, was
then harvested and filtered through a 0.45 μm pose-sized filter,
followed by centrifugation at 35,000 rpm for 3 h at 4 °C using a
Beckman XL-90 ultra centrifuge (Beckman Coulter, Harbor
Boulevard, USA). The pseudoviral pellets were resuspended in
PBS, titrated, aliquoted and stored at −80 °C until use.
Neutralization and blocking assays using the SARS-CoV-S
pseudovirus system
SARS-CoV-S pseudovirus and VSV-G pseudovirus infec-
tion of cells and its neutralization were according to Zhang et al.
(2004). Briefly, Vero E6 cells were seeded in 96-well plates, at a
density of 8×103 cells/well, and cultured overnight. Serially
diluted serum samples or recombinant proteins were mixed with
pseudovirus preparations for 30 min at 37 °C, and then the
mixture added to the wells with monolayer of Vero E6 cells.
After incubation at 37 °C for 1 h, the mixture in the wells was
replaced with fresh medium and the cells were cultured for
additional 48 h. After washes, the cells were lysed using the
luciferase assay reagent (Promega, UAS) and the luciferase
activity in the cell lysate determined using a Veritas microplate
luminometer (Turner Biosystems).
Luciferase activity of the reference group (Vero E6 cells
treated with pseudovirus alone) was taken as 100% infection.
Cells not treated with pseudovirus were included as specificity
control and their luciferase activity readings were at least 3 logs
lower than that of the reference group in all experiments.
Luciferase activity of the experimental groups (Vero E6 cells
treated with pseudovirus preparations in the presence of serum
Abs or blocking reagents) was compared with that of the
reference group and the results, expressed as percent infection,
are calculated as follows: 100×[Luciferase activity of the
experimental groups] / [Luciferase activity of the reference
group].
Statistical analysis
All experiments described here had been repeated at least
3 times. Comparison of the data was performed using the
Student's t test. Significance was defined as a P value
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